Anupam Rasayan completes purchase of 48.2% stake in Bliss GVS Pharma for ₹1,750 cr
29 Sept, 13:36 IST · Plays out within days · 1 source
Anupam Rasayan finished buying a controlling 48.2% of Bliss GVS Pharma for Rs1,750 crore, helping Bliss sellers while Anupam holders face deal cost and debt risk.
Key facts
What the reporting establishes, before any reading of it.
- 48.2% stake acquired for Rs 1,750 crore
- Price Rs 299 per share via SPA
- Includes open offer and on-market top-up
How the news spreads
Step by step — from the first companies it hits to whole sectors.
Who it hits first
- Anupam Rasayan, a maker of specialty chemicals, has finished buying a controlling 48.2% of Bliss GVS Pharma, a drug maker, for Rs1,750 crore at Rs299 per share.
- Bliss GVS shareholders who sold get cash at the deal price, and the stock should trade near Rs299 while the open offer settles.
- Anupam shareholders now own a pharma business too, but the company spent a large sum and takes on more debt and integration work.
Who may gain
- Bliss GVS Pharma selling shareholders receiving Rs299 per share
- Bliss GVS Pharma minority holders if the new owner invests and grows the drug business
- Advisers and brokers who earned fees on the Rs1,750 crore deal and open offer
Along the supply chain
Downstream
UPL, which buys from Anupam Rasayan, sees no change in supply or price from this ownership move, and Bliss GVS has no listed customers in the pack, so downstream flow is flat.
Upstream
Valiant Organics, which supplies materials to Anupam Rasayan, gets no new orders from this share deal — Anupam's factories run as before, so upstream demand is unchanged.
Where demand moves
Business
No new customer demand is created — the same chemicals and drugs are made and sold; only the owner of Bliss shares changes, so business demand flow is flat.
Capital
About Rs1,750 crore of capital flows from Anupam Rasayan to Bliss sellers through the share purchase, open offer, and market top-up, lifting near-term trading in both stocks.
How it spreads across sectors
Chemicals
Neutral — Anupam's cash exit for a pharma asset does not change chemical demand or prices for peers.
Healthcare
Mildly positive mood — a completed Rs299 control price can support small-drug-maker valuations, but no orders move.
When it plays out
Immediate
In 1–7 days both stocks trade on deal arithmetic, with Bliss near Rs299 and Anupam weighed by funding cost; Bliss ASM stage 4 curbs may mute moves.
Medium term
In 1–6 months Anupam must show Bliss earnings adding to group profit; if integration works the deal looks smart, if not the debt load drags.
Short term
In 1–4 weeks the open offer settlement and Anupam's funding details set the tone, with focus on debt taken and pledge levels.